deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT03155100

Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment Lines (KEd)

Phase 2 Study of Carfilzomib + Elotuzumab + Dexamethasone for Relapsed or Progressed Multiple Myeloma After 1-3 Prior Treatment Lines

Sponsor: Amgen

Conditions Multiple Myeloma in Relapse
Interventions Carfilzomib for Inj 60 milligram (MG) Dexamethasone Elotuzumab 400 MG
Updated 12 times since 2017 Last updated: Sep 24, 2023 Started: Aug 7, 2017 Primary completion: Aug 31, 2023 Completion: Aug 31, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Multiple Myeloma in Relapse and is currently completed. Amgen leads this study, which shows 12 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jun 2017 – ~Aug 2017 · 2 months · monthly snapshotNot Yet Recruiting~Aug 2017 – ~Jun 2018 · 10 months · monthly snapshotRecruiting~Jun 2018 – ~Feb 2019 · 8 months · monthly snapshotRecruiting~Feb 2019 – ~Jan 2020 · 11 months · monthly snapshotRecruiting~Jan 2020 – ~Aug 2020 · 7 months · monthly snapshotActive Not Recruiting~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshotActive Not Recruiting~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshotActive Not Recruiting~Mar 2021 – ~Apr 2022 · 13 months · monthly snapshotActive Not Recruiting~Apr 2022 – ~Oct 2023 · 18 months · monthly snapshotActive Not Recruiting~Oct 2023 – ~Jul 2024 · 9 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 24 months · monthly snapshotCompleted

Change History

12 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Oct 2023 — Jul 2024 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  4. Apr 2022 — Oct 2023 [monthly]

    Active Not Recruiting PHASE2

  5. Mar 2021 — Apr 2022 [monthly]

    Active Not Recruiting PHASE2

▶ Show 7 earlier versions

  1. Jan 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE2

  2. Aug 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  3. Jan 2020 — Aug 2020 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Feb 2019 — Jan 2020 [monthly]

    Recruiting PHASE2

  5. Jun 2018 — Feb 2019 [monthly]

    Recruiting PHASE2

  6. Aug 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  7. Jun 2017 — Aug 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Amgen
  • Bristol-Myers Squibb
  • Hospital District of Helsinki and Uusimaa
  • Raija Silvennoinen
Data source: Helsinki University Central Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations